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Background: Carriers of plasminogen activator inhibitor -1 (PAI-1) -675 genotype 5G/5G may be associated with
lower preoperative PAI-1 plasma levels and higher blood loss after heart surgery using cardiopulmonary bypass
(CPB). We speculate if polymorphisms of PAI-1 -844 A/G and angiotensin converting enzyme (ACE) intron 16 I/D also
might promote fibrinolysis and increase postoperative bleeding.
Methods: We assessed PAI-1 -844 A/G, and ACE intron 16 I/D polymorphisms by polymerase chain reaction
technique and direct sequencing of genomic DNA from 83 open heart surgery patients that we have presented
earlier. As primary outcome, accumulated chest tube drainage (CTD) at 4 and 24 h were analyzed for association
with genetic polymorphisms. As secondary outcome, differences in plasma levels of PAI-1, t-PA/PAI-1 complex and
D-dimer were determined for each polymorphism. SPSS® was used for statistical evaluation.
Results: The lowest preoperative PAI-1 plasma levels were associated with PAI-1 -844 genotype G/G, and
higher CTD, as compared with genotype A/A at 4 and 24 h after surgery. Correspondingly, 4 h after the
surgery CTD was higher in carriers of ACE intron 16 genotype I/I, as compared with genotype D/D. PAI-1
plasma levels and t-PA/PAI-1 complex reached nadir in carriers of ACE intron 16 genotype I/I, in whom we
also noticed the highest D-dimer levels immediately after surgery. Notably, carriers of PAI-1 -844 genotype
G/G displayed higher D-dimer levels at 24 h after surgery as compared with those of genotype A/G.
Conclusions: Increased postoperative blood loss secondary to enhanced fibrinolysis was associated with
carriers of PAI-1 -844 G/G and ACE Intron 16 I/I, suggesting that these genotypes might predict increased
postoperative blood loss after cardiac surgery using CPB.Background
Heart surgery by means of cardiopulmonary bypass
(CPB) can impede hemostasis, thereby increasing post-
operative bleeding and the need for blood transfusions
[1, 2]. Recently, investigators reported that more than
40 % of the cases of excessive bleedings after this kind
of surgery are due to coagulopathy [3]. The balance be-
tween bleeding, normal hemostasis and thrombosis is
significantly influenced by platelet aggregation, rate of* Correspondence: lars.bjertnaes@uit.no
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system. Recent evidence suggests that genetic variability
might influence the activation of each of these path-
ways [4, 5].
During CPB, fibrinolytic activity increases 10 - to 100-
fold because of augmented generation of plasmin, trig-
gered by a rise in tissue plasminogen activator (t-PA),
ultimately resulting in enhanced plasma concentration
of fibrin degradation products [6, 7]. Plasminogen acti-
vator inhibitor type-1 (PAI-1), the main inhibitor of
fibrinolysis, increases a 15-fold only 2 h (h) after cardiac
surgery, as a part of the “fibrinolytic shut down” [1, 8].
In a previous study of patients, who underwent cardiac
surgery on CPB, we found that lower plasma concentra-
tions of PAI-1 preoperatively were associated with moreis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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D-dimer concentrations postoperatively [9].
The PAI-1 gene contains more polymorphisms. The
promoter regions 675 4Guanine/5Guanine (4G/5G) and
−844 Adenosine/Guanine (A/G) polymorphisms, both af-
fecting the fibrinolytic balance, are two of the most com-
mon. Reassessing blood from the latter study [9], we
recently confirmed the findings of other investigators that
in addition to decreased plasma levels of PAI-1, excessive
bleeding after CPB was associated with PAI-1 -675 5G/5G
polymorphism [5, 10–14].
Although primarily an endocrine long-term regulator
of blood pressure and extracellular volume, the renin-
angiotensin-aldosterone system (RAAS) also plays a
pivotal role in the regulation of fibrinolysis. Angioten-
sin converting enzyme (ACE) influences PAI-1 plasma
levels by converting angiotensin I to angiotensin II
[15, 16]. Recent studies suggest that increased fibrin-
olysis is mainly related to inhibition of angiotensin II,
which acts by reducing the plasma level of PAI-1 ra-
ther than increasing that of t-PA [17]. However,
plasma concentrations of both PAI-1 and t-PA are
characterized by wide inter-individual variations, most
likely because of differences in ACE plasma concen-
trations [18, 19].
Lately, very long half-life PAI-1 seems to represent a
promising treatment option for genetically predisposed
individuals with low levels of PAI-1 [20]. PAI-1 gene
−844 A/G polymorphism has been associated with both
coronary heart disease [21, 22], and venous thrombosis
resulting from decreased fibrinolysis [22, 23]. However,
to our knowledge, no previous investigation has docu-
mented association between PAI-1 -844 A/G poly-
morphism and increased blood loss due to increased
fibrinolysis after cardiac surgery employing CPB.
Intron 16 Insertion/Deletion (I/D) polymorphism of
the ACE gene influences concentration of circulating
ACE, thereby affecting endogenously generated inhibitor
of fibrinolysis. The insertion allele is believed to steer
approximately one half of the plasma levels of ACE and
PAI-1, and might potentially increase fibrinolytic activ-
ity [24]. Several studies have revealed that ACE intron
16 I/D polymorphism is accompanied by a wide range
of cardiovascular diseases. Genotype D/D is associated
both with increased plasma concentration and higher
activity of PAI-1 [25–28]. However, the ACE Intron 16
I/D polymorphism has been sparsely studied, as a
potential cause of postoperative bleeding, and with con-
troversial results [25, 29, 30]. Consequently, by examin-
ing the same patient cohort as referred to above [14],
our primary end-point was to address the associations
between PAI-1 -844 A/G and ACE Intron 16 I/D poly-
morphisms and fibrinolytic bleeding after cardiac sur-
gery using CPB.Methods
Methods has been presented previously in this journal
[9] and will only be shortly described. A more extensive
version is available, see Additional file 1. The protocol
and the informed consent form, including the request to
donate genetic material, were approved by the Ethics
Committee of Pauls Stradins Clinical University Hos-
pital, Riga, Latvia. All patients provided written informed
content.
In short, 90 consecutive adult patients were admitted
to the hospital to undergo cardiac surgery with CPB,
whereof 7 were excluded at the reoperation because of
surgical bleeding. Postoperative bleeding volumes were
recorded as chest tube drainage (CTD) in mL at 4 and
24 h after the surgery [9]. Inclusion and exclusion cri-
teria, as well as perioperative management, postoperative
bleeding and demographic and laboratory data were the
same as published before [9] and genomic DNA was
extracted as reported by Ozolina et al. [14]. Here, we
only describe the methods used for analysis of PAI-1 -844
A/G and ACE Intron 16 I/D polymorphisms.
PAI-1 -844 A/G and ACE Intron 16 I/D
Genomic DNA from whole blood of every patient was
diluted in 1 ml of water and stored on minus 70 °C until
analyzed. The region harboring the PAI-1 -844 A/G gene
polymorphism was amplified using polymerase chain re-
action (PCR). The primers had the following sequences:
5′-ATCCCTTTTCCCCTTGTGTC-3′ and 5′-AACCTC
CATCAAAACGTGGA-3′. The PCR products were then
purified using Sap/Exo I (Thermo Scientific® Fermentas,
Lithuania) and sequenced on an ABI Prizm 3130xl
genetic analyzer (Applied Biosystems®, Life Technologies,
USA).
For determination of ACE Intron16 I/D polymorph-
ism, we used the method published by Tomita et al.
[31]. Insertion and deletion alleles were identified by
using PCR amplification of the respective fragments
from Intron 16. Fragment size was determined by agar-
ose gel electrophoresis. The deletion allele was visualized
at 191 base pairs (bp), and an insertion allele at 478 bp.
For patients with /D genotype additional PCR was
performed to verify the result of amplification.
Statistical analysis
Data were analyzed with SPSS (SPSS® version 20.0,
Chicago, IL). Continuous variables were presented as
mean ± standard deviation (SD) and categorical vari-
ables as percentages (%). The data of the study
groups were checked by an appropriate analytic test
according to the data distribution. Comparisons be-
tween genotype groups were performed with Kruskal-
Wallis H test for non-parametric variables, and with
ANOVA for parametric variables. Chi-square test was
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cance was defined as P < 0.05.
Results
Clinical course
Out of totally, 90 consecutive patients scheduled for first
time cardiac surgery, 83 patients, 42 men and 41
women, who met inclusion criteria were subjected to
further analysis (Table 1). Patients were classified with
their PAI-1-844 A/G and ACE Intron 16 I/D charac-
teristics and subdivided into 3 groups, according to
the genotype of each polymorphism. The genotype
results of PAI-1 -844 A/G and ACE Intron 16 I/D
polymorphisms were all in Hardy-Weinberg equilib-
rium. We noticed no significant differences between
CPB priming - and cardioplegia volumes in relation
to the different genotypes. We found no associations
between PAI-1 -844 A/G genotype and demographic
characteristics, preoperative parameters and surgical
variables (Table 1). ACE of genotypes I/D and D/DTable 1 Perioperative characteristics of patients scheduled for on-pu
Characteristics PAI-1 -844 A/G
Genotype G/G A/G
Number of patients, n 22 387
Demographic data
Age, yr 61 ± 11 68 ± 10
Male sex, n (%) 15 (68) 16 (42)
BMI, kg/m2 28 ± 5 28 ± 8
EF, (%) 57 ± 8 55 ± 8
Type of surgery, n (%)
CABG, n (%) 11 (50) 15 (40)
Valve, n (%) 8 (36) 13 (34)
Mixed, n (%) 3 (14) 10 (26)
Surgical variables
CPB duration (min) 110 ± 42 106 ± 42
Aorta oclusion time (min) 69 ± 30 65 ± 25
Reperfusion time (min) 33 ± 12 33 ± 15
CPB priming volume, ml 1864 ± 543 1509 ± 516
Cardioplegia, ml 1872 ± 587 1673 ± 516
Preoperative parameters
Hemoglobin, g/dL 136 ± 15 139 ± 13
Platelet count, × 109/L 221 ± 67 215 ± 50
Prothrombin time, % 84 ± 15 90 ± 14
Fibrinogen, g/L 4.4 ± 1.3 4.6 ± 1.2
Data presented as the mean ± standard error of the mean
PAI-1 Plasminogen activator inhibitor type-1, A Adenosine, G Guanine, ACE Angioten
mass index, EF Ejection fraction, CABG Coronary artery bypass grafting, CPB Cardiop
**P < 0.05 between ACE Intron 16 D/D andI/D genotypeswere significantly more represented among males
(P < 0.05) and in patients undergoing mixed type of
surgery (P < 0.05).
Relationships between PAI-1 -844 A/G and ACE Intron 16
I/D polymorphisms and postoperative bleeding
Table 2 shows preoperative PAI-1, postoperative t-PA/
PAI-1 complex and D-dimer plasma levels in relation
to PAI-1-844 A/G and ACE Intron 16 I/D poly-
morphisms. Mean PAI-1 plasma concentration was
lower in carriers of genotype G/G, as compared to A/
A (P = 0.004), but no significant difference existed be-
tween genotypes A/A and A/G. Mean plasma concen-
trations of t-PA/PAI-1 complex determined 24 h
postoperatively displayed no significant differences
between the PAI-1-844 genotype groups. In contrast,
D-dimer levels differed significantly between carriers
of genotypes G/G and A/G (P = 0.04) at 24 h
(Table 2). As depicted in Fig. 1, carriers of PAI-1-844
genotype G/G displayed the greatest blood loss at 4mp cardiac surgery
ACE Intron 16 I/D
A/A I/I I/D D/D
23 22 42 19
67 ± 11 68 ± 10 66 ± 10 63 ± 14
11 (48) 9 (41)* 23 (55)* ** 10 (53)**
27 ± 5 27 ± 5 28 ± 5 27 ± 4
56 ± 7 58 ± 6 55 ± 9 55 ± 7
8 (35) 8 (36) 18 (43) 8 (42)
10 (43) 9 (41) 13 (31) 9 (47)
5 (22) 5 (23)* 11 (26)* ** 2(11)**
99 ± 37 101 ± 47 105 ± 39 109 ± 37
63 ± 11 64 ± 27 65 ± 27 69 ± 29
33 ± 16 29 ± 13 36 ± 17 33 ± 9
1329 ± 440 1379 ± 462 1548 ± 556 1544 ± 482
1886 ± 674 1647 ± 523 1833 ± 655 1836 ± 478
131 ± 18 132 ± 17 137 ± 16 138 ± 12
215 ± 63 211 ± 45 218 ± 65 220 ± 58
92 ± 12 94 ± 15 89 ± 13 85 ± 14
4.7 ± 1.5 4.5 ± 1.2 4.6 ± 1.2 4.7 ± 3.7
sin converting enzyme, I Insertion, D Deletion, n Number of patients, BMI Body
ulmonary bypass. *P < 0.05 between ACE Intron 16 I/I and I/D genotypes;
Table 2 PAI-1 -844 A/G and ACE Intron 16 I/D gene polymorphisms related to markers of fibrinolysis. Plasma concentrations of PAI-1
preoperatively – and of t-PA/PAI-1 complex and D-dimer postoperatively after on-pump cardiac surgery




D-dimer, ng/mL 0 h D-dimer, ng/mL 6 h D-dimer, ng/mL 24 h
PAI-1 -844 A/G
A/A 23 28 ± 12* 3.8 ± 1.8 251 ± 170 289 ± 210 234 ± 187
A/G 38 24 ± 13 3.6 ± 2.1 312 ± 213 312 ± 200 184 ± 129*
G/G 22 18 ± 12* 3.4 ± 2.4 287 ± 255 255 ± 203 267 ± 168*
P value 0.004 NS NS NS 0.04
ACE intron 16 I/D
D/D 19 27 ± 13* 3.6 ± 2 234 ± 161* 244 ± 182 208 ± 173
I/D 42 24 ± 13 4 ± 2.3* 294 ± 238 291 ± 204 247 ± 165
I/I 22 18 ± 11* 2.8 ± 1.7* 376 ± 203* 331 ± 218 274 ± 167
P value 0.02 0.02 0.03 NS NS
Data presented as the mean ± standard error of the mean
PAI-1 Plasminogen activator inhibitor type-1, A Adenosine, G Guanine, ACE Angiotensin converting enzyme, I Insertion, D Deletion, n Number of patients,
t-PA Tissue plasminogen activator, 0 h Immediately after surgery, 6, 24 h 6 and 24 h postoperatively. *P < 0.05 between genotypes
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of genotype A/A (P = 0.0001, P = 0.03, respectively).
Carriers of ACE Intron 16 genotype I/I presented with
significantly lower preoperative plasma concentrations
of PAI-1, as compared with carriers of genotype D/D
(P = 0.02), but not as compared with carriers of geno-
type I/D (Table 2). Concerning t-PA/PAI-1 complex
determined 24 h after the surgery (Table 2), we found
higher plasma concentrations in carriers of genotypesFig. 1 PAI-1-844 A/G polymorphism and blood loss after open heart
surgery. Relationship between PAI-1 -844 A/G polymorphism and
accumulated postoperative blood loss after cardiac surgery with
cardiopulmonary bypass. Data presented as the mean ± standard
error of the mean. PAI-1, Plasminogen activator inhibitor type −1; A,
adenosine; G, guanine; mL, milliliters; h, hours. *P < 0.05 4 h blood loss
between PAI-1 -844 of genotypes G/G and A/A; † P < 0.05 between
24 h blood loss associated with genotypes G/G and A/A of PAI-1 -844;
& P < 0.05 between 24 h blood loss associated with PAI-1 -844 of
genotypes A/G and A/AI/D as compared with I/I (P = 0.02). Postoperatively,
patients with ACE Intron 16 genotype I/I displayed
higher plasma concentrations of D-dimer at all three
time points. The difference reached significance im-
mediately after the surgery (Table 2) in carriers of
genotype I/I in comparison with genotype D/D (P = 0.03).
Correspondingly, as shown in Fig. 2, carriers of genotype
I/I also presented with significantly higher blood loss 4 h
after surgery, in comparison with genotypes I/D (P = 0.02)
and D/D (P = 0.04).Fig. 2 ACE Intron 16 I/D polymorphism and blood loss after open
heart surgery. Relationship between ACE Intron 16 I/D polymorphism
and accumulated postoperative blood loss after cardiac surgery with
cardiopulmonary bypass. Data presented as the mean ± standard
error of the mean. ACE, Angiotensin Converting Enzyme; I, insertion;
D, deletion; mL, milliliters; h, hours. # P < 0.05 between 4 h blood
loss associated with ACE Intron 16 of genotypes I/I and D/D; ‡ P < 0.05
between 4 h blood loss associated with ACE Intron 16 of genotypes I/I
and I/D
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This study revealed that blood loss after cardiac surgery
with extracorporeal circulation is larger in carriers of
PAI-1 -844 genotype G/G and ACE intron 16 genotype
I/I as compared with their respective genotypes A/A and
D/D. We also noticed the lowest preoperative plasma
concentrations of PAI-1 and the highest D-dimer levels
24 h after the surgery in carriers of PAI-1-844 genotype
G/G. Correspondingly, in carriers of ACE intron 16
genotype I/I, D-dimer plasma concentration peaked
transiently immediately after the surgery and t-PA/PAI-1
complex reached nadir at 24 h postoperatively.
PAI-1 and t-PA forming t-PA/PAI-1 complex, are sup-
posed to be the main regulators of fibrinolysis in human.
According to a recent study, patients with myocardial in-
farction presented with higher PAI-1 and lower t-PA
plasma concentrations as compared with healthy controls
[21]. Notably, regression analysis confirmed an independ-
ent association between myocardial infarction and geno-
type -844 A/A in concert with pronounced elevation of
PAI-1 [22]. Consistent with the increased anti-fibrinolytic
activity associated with myocardial infarction, our findings
indicate that genotype A/A rather protects against fibrin-
olysis, as assessed by a lower accumulated blood loss 24 h
postoperatively in carriers of that genotype.
PAI-1-844 A/G polymorphisms
We believe that increased fibrinolysis, as assessed by
lower plasma concentrations of PAI-1 and t-PA/PAI-1
complex can explain the augmented blood loss in
carriers of PAI-1-844 genotype G/G. As compared with
heterozygotes and carriers of PAI-1 -844 A/A, those of
genotype G/G presented with significantly larger blood
loss and the significantly highest D-dimer plasma con-
centrations at 24 h. The latter genotype also demon-
strated a 36 % reduction in preoperative PAI-1 plasma
concentration, as compared with carriers of genotype
A/A. This is consistent with observations made by pre-
vious investigators in healthy volunteers [32]. Studying
PAI-1-844 A/G and PAI-1 -675 (4G/5G) polymor-
phisms, the latter workers showed that carriers of
genotype G-5G had significantly lower plasma concen-
trations of PAI-1. They also noticed that the plasma
level of PAI-1 depends more on body mass index than
on PAI-1 promoter variations, a contention we could
not confirm in the present study. In carriers of genotype
G/G, we also were unable to demonstrate increased
fibrinolysis at 0 and 6 h postoperatively, despite the fact
that this genotype displayed the significantly highest
plasma level of D-dimer 24 h after surgery. We interpret
this result as a of lower inhibitory fibrinolytic potential,
which is consistent with the “fibrinolytic shut down”,
that might occur in parallel with maximum D-dimer
levels 24 h after the operation [33].ACE Intron 16 I/D polymorphisms
Several investigators have focused on a potential asso-
ciation between ACE Intron 16 I/D polymorphism
and increased postoperative bleeding after cardiac surgery
[25, 28–30, 34]. Prior to surgery, we observed 33 % signifi-
cantly higher preoperative plasma concentrations of PAI-1
in carriers of ACE Intron 16 of genotype D/D, as com-
pared with genotype I/I. The latter genotype also displayed
significantly lower plasma levels of t-PA/PAI-1 complex
and higher levels of D-dimer postoperatively, as compared
with genotype I/D. The finding that those with the D-
allele displayed the highest plasma levels of PAI-1 agrees
with a report evaluating the association between plasma
PAI-1 levels and ACE Intron 16 I/D polymorphism in
healthy volunteers [18]. Despite we observed more blood
loss 4 h after the surgery in carriers of genotype I/I, we
found no significant differences between the three geno-
types 24 h postoperatively. Most likely, the increased
blood loss was caused by fibrinolysis. According to previ-
ous investigators, plasma concentration of PAI-1 does not
rise earlier than 2–3 h after the surgery [1]. The fact that
carriers of genotype I/I had the lowest postoperative levels
of t-PA/PAI-1 complex (Table 2) strengthens the assump-
tion of an increased fibrinolytic tendency in association
with that particular genotype. Other investigators also
have reported significant associations between ACE 16 I/D
polymorphism and postoperative blood loss 12 and 24 h
after open heart surgery [28, 29]. In one investigation, the
D allele was associated with decreased bleeding consistent
with our finding [28]. In contrast, other investigators
found larger blood loss 24 h postoperatively in carriers of
ACE Intron 16 genotype I/I [30].
In carriers of ACE Intron 16 genotype D/D undergoing
non-cardiac surgery, researchers observed decreased
bleeding tendency in association with higher plasma con-
centrations of ACE [28]. Investigators studying the influ-
ence of ACE polymorphism on intra – and postoperative
bleeding in patients undergoing total hip replacement
showed that carriers of D/D and I/D genotypes had the
highest total blood losses [25]. In contrast to our findings,
these workers suggest that the D allele should be consid-
ered as a risk factor of increased bleeding. In their work,
patients of genotype I/I displayed higher D-dimer concen-
trations, suggesting that more efficient activation of co-
agulation had taken place, consistent with the higher D-
dimer levels observed immediately after surgery in the
present study. However, the latter investigators did not de-
termine the PAI-1 and t-PA/PAI-1 plasma concentrations
that corresponded with the ACE 16 I/D polymorphism.
Possibly, higher plasma levels of ACE, PAI-1 and t-PA/
PAI-1 complex, combined with angiotensin-II-induced in-
crease in vasoconstrictor tone, could explain these find-
ings. Thus, although no general agreement has been
reached, we and other investigators support the idea that
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ACE Intron 16 of genotype I/I [29, 30, 34].
Limitations
Firstly, we admit that the sample size was too low to reach
significant difference with, at least 80 % power, and 5 % sig-
nificance level for analysis of every genetic polymorphism.
We compared t-PA/PAI-1 complex plasma concentrations
of 22 and 23 patients of genotypes G/G and A/A, respect-
ively, and found that sample sizes of at least 159 patients in
each group would be required to reach significant differ-
ences between the genotypes (Table 2). We wondered
whether simultaneous occurrence of PAI-1 -844 G/G and
ACE Intron 16 I/I would give rise to excessive blood loss,
or that PAI-1 -844 A/A and ACE Intron 16 D/D would re-
sult in less blood loss postoperatively, but sample sizes
were too low for such analysis. We also admit as a weak-
ness that we did not include a group of healthy volunteers.
We correlated two gene polymorphisms with the
plasma concentrations of individual fibrinolytic factors,
but do admit that other confounding factors, like
hypothermia, hemodilution, heparin re-bound and plate-
let damage also might have affected postoperative blood
loss after surgery. Some investigators argue that reduc-
tion of body temperature lowers endogenous production
of PAI-1, thereby giving rise to enhanced fibrinolysis
and increased bleeding [35], whereas others refute this
idea [36]. We rewarmed the patients to normal body
temperature (36.6 °C) before transfer to the recovery
rooms. Therefore, it is unlikely that hypothermia re-
duced the formation of t-PA/PAI-1 complex and in-
creased postoperative bleeding in these patients.
Consumption of coagulation factors and hemodilution
(Table 1) also might have contributed to increased blood
loss postoperatively [37]. We do not deny, that t-PA/
PAI-1 plasma levels occasionally decreased 24 h after
the surgery due to the combination of hemodilution and
decreased anti-fibrinolytic plasma proteins [6]. However,
at 24 h postoperatively, we assume that patients had
regained normovolemia because a negative net fluid
balance was created upon admission to ICU.
It is hard to distinguish clinically changes in fibrinolysis
from coagulation disturbances. We admit as a limitation,
that neither euglobulin clot lysis time nor thromboelasto-
graphy/thromboelastometry (TEG/ROTEM) were per-
formed, although some studies predicate a limited role of
the latter tests for detecting fibrinolysis [38, 39]. Accord-
ing to recent studies, TEG/ROTEM can only detect severe
fibrinolysis in 5 % of cases as compared to 57 % of the
cases of moderate fibrinolysis diagnosed with fibrinolytic
markers, such as antiplasmin-plasmin complex [39].
Lower thresholds have been suggested for detecing 30-
minute fibrinolysis (LY30) by TEG [38]. Despite the fact
that our patients received tranexamic acid during CPB,fibrinolytic markers were analyzed only preoperatively and
at 24 h postoperatively. At the latter time point, we as-
sume that 90 % of the anti-fibrinolytic agents were ex-
creted via the urine [40]. Nonetheless, after elimination of
other possible causes of bleeding, we found a correlation
between our commonly used markers of fibrinolysis and
specific genotypes.
Conclusions
The present study demonstrates that increased postopera-
tive blood loss in patients subjected to cardiac surgery with
the use of CPB might be caused by increased fibrinolysis
secondary to decreased plasma concentration of PAI-1 due
to PAI-1 -844 G/G or ACE Intron 16 I/I polymorphisms.
We suggest that screening for genetic polymorphisms
might become part of future pre-operative routines in
order to prevent risks for postoperative bleeding due to
disorders in the coagulation – or the fibrinolytic systems.
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